Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

T, Facon; MA, Dimopoulos; A, Dispenzieri; JV, Catalano; A, Belch; M, Cavo; A, Pinto; K, Weisel; H, Ludwig; NJ, Bahlis; A, Banos; M, Tiab; M, Delforge; JD, Cavenagh; C, Geraldes; JJ, Lee; C, Chen; A, Oriol; La Rubia J, De; D, White; D, Binder; J, Lu; KC, Anderson; P, Moreau; M, Attal; A, Perrot; B, Arnulf; L, Qiu; M, Roussel; E, Boyle; S, Manier; M, Mohty; H, Avet-Loiseau; X, Leleu; A, Ervin-Haynes; G, Chen; V, Houck; L, Benboubker; C, Hulin

doi:10.1182/blood-2017-07-795047

Public

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Shared by NobleBlocks on Nov 17, 2017 • 12:00 AM UTC

Authors:

Facon T

Dimopoulos MA

Dispenzieri A

Abstract

This FIRST trial final analysis examined survival outcomes in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and t...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!